×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALT – altimmune, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/3
03:55 pm
alt
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]
Neutral
Report
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]
2/2
10:02 am
alt
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]
Low
Report
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]
1/29
05:54 pm
alt
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Medium
Report
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
1/29
01:31 pm
alt
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Low
Report
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
1/29
07:41 am
alt
Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
09:25 pm
alt
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
High
Report
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
1/27
06:00 pm
alt
Altimmune (NASDAQ:ALT) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
High
Report
Altimmune (NASDAQ:ALT) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/5
07:54 am
alt
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
Low
Report
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
11/12
08:46 am
Reiterates
Market Outperform
Market Outperform
Citigroup Inc.
Low
Report
-1.6%
Date
Time
Symbol
Headline
Impact
2/3
04:16 pm
alt
Form 4 Altimmune, Inc. For: Jan 30 Filed by: Roberts M Scot
Medium
Report
Form 4 Altimmune, Inc. For: Jan 30 Filed by: Roberts M Scot
2/3
04:05 pm
alt
Form 8-K Altimmune, Inc. For: Feb 02
Medium
Report
Form 8-K Altimmune, Inc. For: Feb 02
2/2
04:16 pm
alt
Form 4 Altimmune, Inc. For: Jan 30 Filed by: Garg Vipin K
Low
Report
Form 4 Altimmune, Inc. For: Jan 30 Filed by: Garg Vipin K
2/2
04:10 pm
alt
Form 4 Altimmune, Inc. For: Jan 31 Filed by: Jordt Raymond M
Low
Report
Form 4 Altimmune, Inc. For: Jan 31 Filed by: Jordt Raymond M
1/30
01:26 pm
alt
Form SCHEDULE 13G/A Altimmune, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Altimmune, Inc. Filed by: VANGUARD GROUP INC
1/29
04:15 pm
alt
Form 4 Altimmune, Inc. For: Jan 27 Filed by: Jordt Raymond M
Medium
Report
Form 4 Altimmune, Inc. For: Jan 27 Filed by: Jordt Raymond M
1/29
04:10 pm
alt
Form 4 Altimmune, Inc. For: Jan 27 Filed by: Garg Vipin K
Medium
Report
Form 4 Altimmune, Inc. For: Jan 27 Filed by: Garg Vipin K
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/28
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
29.8%
3/4 Altimmune (ALT) Presenta At Cowen Health Care Conference - Slideshow [Seeking Alpha] 18.2%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 7.5%
6/12 Form 8-K Altimmune, Inc. For: Jun 10 5.5%
2/4 Form 4 Altimmune, Inc. For: Jan 31 Filed by: Roberts M Scot 3.4%
5/15 Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 1.9%
11/21 Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH 1.8%
4/8 Form 8-K Altimmune, Inc. For: Apr 02 1.8%
6/12 Altimmune Appoints Will Brown as Chief Financial Officer 1.7%
8/14 Form S-8 Altimmune, Inc. 1.5%
3/4 Altimmune (ALT) Presenta At Cowen Health Care Conference - Slideshow [Seeking Alpha] 18.2%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 7.5%
6/12 Form 8-K Altimmune, Inc. For: Jun 10 5.5%
2/4 Form 4 Altimmune, Inc. For: Jan 31 Filed by: Roberts M Scot 3.4%
5/15 Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 1.9%
11/21 Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH 1.8%
4/8 Form 8-K Altimmune, Inc. For: Apr 02 1.8%
6/12 Altimmune Appoints Will Brown as Chief Financial Officer 1.7%
8/14 Form S-8 Altimmune, Inc. 1.5%
TOP News Decliners
3/9
Thinking about buying stock in Aurora Cannabis, Altimmune, Chesapeake Energy Corp, Nokia, or Sprint?
-20.8%
7/9 Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio -14.2%
3/30 Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine -13.7%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 -13.4%
1/23 Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer -12.6%
3/3 Form 4 Altimmune, Inc. For: Feb 29 Filed by: Garg Vipin K -12.0%
8/21 Form 8-K Altimmune, Inc. For: Aug 20 -11.7%
11/13 Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update -10.1%
6/10 Altimmune Announces Successful Pre-IND Meeting with FDA -10.0%
6/5 Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs -9.6%
7/9 Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio -14.2%
3/30 Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine -13.7%
3/27 Form 8-K Altimmune, Inc. For: Mar 27 -13.4%
1/23 Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer -12.6%
3/3 Form 4 Altimmune, Inc. For: Feb 29 Filed by: Garg Vipin K -12.0%
8/21 Form 8-K Altimmune, Inc. For: Aug 20 -11.7%
11/13 Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update -10.1%
6/10 Altimmune Announces Successful Pre-IND Meeting with FDA -10.0%
6/5 Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs -9.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: